EUCTR2007-002007-41-IT进行中（未招募）不适用
A Phase II Clinical Trial of Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine (XELOX) Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases - ND
AZIENDA OSPEDALIERA ORDINE MAURIZIANO0 个研究点开始时间: 2007年11月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically proven colorectal adenocarcinoma Stage IV disease, with liver involvement ± regional lymphonodes Number and extent of hepatic metastases: - > 3 liver metastases - > 50% hepatic involvement requiring a major hepatectomy with controlateral wedge resection - Any metastases requiring a resection not fulfilling the following criteria: (1) the ability to preserve two contiguous hepatic segments, (2)preservation of adequate vascular inflow and outflow as well as biliary drainage, and (3) the ability to preserve adequate future liver remnant No previous chemotherapy No previous radiotherapy ECOG Performance status < or = 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Other primary solid tumor treated less then 5 years prior to enrollment Adenocarcinoma of the middle and /or lower rectum (within 12 cm from the anal verge) Extrahepatic metastasis, other than regional lymph nodes Subjects may have received prior fluoropyrimidine therapy if administered solely for the purpose of radiosensitization Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, erlotinib)
研究者
相似试验
进行中（未招募）
不适用
An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer.Ensayo Clínico fase II de Panitumumab combinado con quimioterapia de Irinotecan como tratamiento de segunda linea en sujetos con cáncer colorectal metastásico.EUCTR2006-006363-24-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)80
已完成
2 期
Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000011440onprofit Organization Japan Clinical Cancer Research Organization35
招募中
2 期
Multicenter phase II trial of panitumumab plus irinotecan and S-1 (PIRIS regimen) in patients treated by oxaliplatin-based chemotherapy with K-RAS wild-type advanced colorectal cancer.Colorectal CancerJPRN-UMIN000004574Showa University Nothern Yokohama Hospital48
已完成
4 期
Combination therapy trial of panitumumab(Pmab) with FOLFIRI for inoperable advanced recurrent colorectal cancer first-line chemotherapyadvanced and recurrent colorectal cancerJPRN-UMIN000005196Kyoto Prefectural University of Medicine70
进行中（未招募）
不适用
Estudio clínico abierto de fase II de panitumumab en combinación con quimioterapiaFOLFIRI como tratamiento de segunda línea en sujetos con cáncer colorrectalmetastásico que expresa KRAS no mutado y que haya progresado ≥ 6 meses despuésde la última dosis de la quimioterapia de primera línea - ACTIVECáncer colorrectal metastásico que expresa KRAS no mutadoEUCTR2009-010975-26-ESAssociació Catalana per a la Recerca Oncológica i les seves implicacions Sanitáries i Socials